NeuroSense Therapeutics Ltd. SEC filings NRSN
NeuroSense Therapeutics Ltd. has 314 filings in SEC EDGAR's recent list, going back to Aug 9, 2021. Its latest annual report, Form 20-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 31, 2026 | — |
| EFFECT | Filing | Nov 25, 2025 | — |
| CORRESP | Letter to the SEC | Nov 24, 2025 | — |
| EFFECT | Filing | Aug 18, 2025 | — |
| EFFECT | Filing | Aug 18, 2025 | — |
| EFFECT | Filing | Apr 16, 2025 | — |
| EFFECT | Filing | Apr 16, 2025 | — |
| EFFECT | Filing | Jan 16, 2025 | — |
| CORRESP | Letter to the SEC | Jan 16, 2025 | — |
| CORRESP | Letter to the SEC | Jan 6, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2025 | — |
| EFFECT | Filing | Dec 12, 2024 | — |
| D | Filing | Dec 12, 2024 | — |
| CORRESP | Letter to the SEC | Dec 12, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2024 | — |
| EFFECT | Filing | Nov 22, 2024 | — |
| CORRESP | Letter to the SEC | Nov 21, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2024 | — |
| EFFECT | Filing | Oct 4, 2024 | — |
| EFFECT | Filing | May 22, 2024 | — |
| CORRESP | Letter to the SEC | May 21, 2024 | — |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| D | Filing | Apr 25, 2024 | — |
| EFFECT | Filing | Apr 8, 2024 | — |
| EFFECT | Filing | Apr 8, 2024 | — |
| EFFECT | Filing | Dec 4, 2023 | — |
| CORRESP | Letter to the SEC | Dec 4, 2023 | — |
| EFFECT | Filing | Sep 5, 2023 | — |
| CORRESP | Letter to the SEC | Aug 31, 2023 | — |
| CORRESP | Letter to the SEC | Aug 14, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 1, 2023 | — |
| D | Filing | Jul 5, 2023 | — |
| EFFECT | Filing | Jan 30, 2023 | — |
| CORRESP | Letter to the SEC | Jan 26, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 26, 2023 | — |
| POS EX | Filing | Apr 28, 2022 | — |
| AW | Acceleration withdrawal | Apr 28, 2022 | — |
| EFFECT | Filing | Dec 8, 2021 | — |
| CERT | 8a cert | Dec 8, 2021 | — |
| CORRESP | Letter to the SEC | Dec 6, 2021 | — |
| CORRESP | Letter to the SEC | Dec 6, 2021 | — |
| CORRESP | Letter to the SEC | Nov 19, 2021 | — |
| 8-A12B | For registration of certain classes | Nov 18, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2021 | — |
| CORRESP | Letter to the SEC | Nov 4, 2021 | — |
| CORRESP | Letter to the SEC | Oct 18, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 15, 2021 | — |
| DRS/A | Filing | Oct 7, 2021 | — |
| DRSLTR | Filing | Oct 6, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 1, 2021 | — |
| DRSLTR | Filing | Sep 21, 2021 | — |
| DRS/A | Filing | Sep 21, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 3, 2021 | — |
| DRS | Filing | Aug 10, 2021 | — |
| DRSLTR | Filing | Aug 9, 2021 | — |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRSN (Nasdaq), NRSNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Herzliya, Israel
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1875091
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.